Π

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

				. ,								
1. Name and Address of Reporting Person* Lampropoulos Justin J.				suer Name and Tick	•	Symbol E <u>MS INC</u> [MMSI	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
			[]			X	Officer (give title below)		(specify			
(Last) 1600 WEST ME	(First) RIT PARKWAY		te of Earliest Transa 6/2018	action (Month/	Day/Year)	EVP GLOBAL SALES, MKTG & STG						
(Street) SOUTH			4. If A	Amendment, Date of	f Original Filed	(Month/Day/Year)	6. Indiv Line)	idual or Joint/Group	Filing (Check A	pplicable		
JORDAN	UT	84095					X	Form filed by One	Reporting Pers	on		
								Form filed by Mor Person	e than One Rep	orting		
(City)	(State)	(Zip)										
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1. Title of Security (Instr. 3) 2. Transac				2A. Deemed	3.	4. Securities Acquired (A)	or	5. Amount of	6. Ownership	7. Nature of		

Execution Date, Transaction Disposed Of (D) (Instr. 3, 4 and 5) ecurities orm: Direct Indirect Date Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) (D) or Indirect (I) (Instr. 4) (Month/Day/Year) if any (Month/Day/Year) Beneficial Code (Instr. Ownership (Instr. 4) 8) (A) or (D) Code v Amount Price Common Stock, No Par Value 11/16/2018 М 20,000 Α \$12.06 20,000 D 11/16/2018 s 20.000 D **\$61.01**⁽¹⁾ 0 D Common Stock, No Par Value

Common	Stock, NO	Par value			.6/2018	5			5		20,000	D	\$61.01	1)	0	D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisabl	le	Expiration Date	Title	Amount or Number of Shares				
Non- qualified stock options (right to buy)	\$13.14								07/31/2014	(2)	07/31/2020	Common Stock	8,000		8,000	D	
Non- qualified stock options (right to buy)	\$12.06	11/16/2018			М			20,000	10/04/2015	5 ⁽³⁾	10/04/2021	Common Stock	20,000	\$0	5,000	D	
Non- qualified stock options (right to buy)	\$17.27								02/13/2016	5(4)	02/13/2022	Common Stock	20,000		20,000	D	
Non- qualified stock options (right to buy)	\$16.05								01/28/2017	7(5)	01/28/2023	Common Stock	20,000		20,000	D	
Non- qualified stock options (right to buy)	\$28.2								04/14/2018	3 ⁽⁶⁾	04/14/2024	Common Stock	25,000		25,000	D	
Non- qualified stock options (right to buy)	\$44.8								03/02/2019) (7)	03/02/2025	Common Stock	20,000		20,000	D	
Explanatio	n of Respons	ses:															

1. The price reported in Column 4 of Table 1 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$60.155 to \$61.400, inclusive. The Reporting Person undertakes to provide to Merit Medical Systems, Inc., any security holder of Merit Medical Systems, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

2. Became exercisable in equal annual installments of 20% commencing on 07/31/2014.

- 3. Becomes exercisable in equal annual installments of 20% commencing on 10/04/2015.
- 4. Becomes exercisable in equal annual installments of 20% commencing on 02/13/2016.
- 5. Becomes exercisable in equal annual installments of 20% commencing on 01/28/2017.
- 6. Becomes exercisable in equal annual installments of 20% commencing on 04/14/2018.7. Becomes exercisable in equal annual installments of 20% commencing on 03/02/2019.

Remarks:

Brian G. Lloyd, Attorney-in-Fact

11/20/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.